Revtorpyk (gedatolisib)

Where it stands

According to the official record, the US FDA approved Revtorpyk (gedatolisib) on 2026-07-14. The sponsor is Celcuity, the application is NDA219908, and the product is listed as a new medicine in powder form.

The records do not state the approved indication, the therapeutic area, or the patient population. This analysis therefore cannot describe what the product is approved to treat, the dosing, or the line of therapy. Readers should consult the FDA approval letter and the final prescribing information for these details.

The record is US-only. No CHMP opinion date is listed, and no EU, UK or other regional filing or decision is mentioned. Nothing in the data indicates the status of any ex-US application.

Regulatory pathway and designations

The record lists two designations: New molecular entity (NME) and Priority review. An NME designation means the active ingredient had not previously been approved by the FDA, and the application was submitted as a new drug application (NDA), consistent with NDA219908.

Priority review is an FDA review designation that sets a shorter target review timeline than standard review, generally reserved for products that may offer significant improvements in the treatment, diagnosis or prevention of serious conditions. The records do not say which basis applied here. They also do not give the submission date, the PDUFA goal date, or whether other expedited programs (e.g. Breakthrough Therapy, Fast Track) or an accelerated approval pathway were involved, so none of these should be assumed.

The only milestone recorded is the approval itself, flagged as an official source. Interim steps such as advisory committee meetings, complete response letters or review extensions are not in the data.

Safety and pharmacovigilance

The records contain no safety information: no adverse event profile, boxed warning, contraindications, REMS, or postmarketing requirements or commitments. No clinical trial results are provided either.

For a newly approved NME, the FDA label and any postmarketing requirements are the primary sources for the safety profile and the ongoing monitoring plan. Routine pharmacovigilance, including adverse event reporting through FAERS, applies after approval. Specific conclusions about this product's risks cannot be drawn from the data provided.

What to watch

Based on the records alone, the first priority is to obtain the full prescribing information to confirm the indication, population, dosing and safety language, as these are missing from the data.

Other items to monitor, none of which are confirmed in the records, include any postmarketing study requirements, the launch timing and availability from Celcuity, and whether regulatory submissions are made or progressed in other regions such as the EU, where a CHMP opinion would be the relevant milestone. No dates or outcomes for these are given and none should be inferred.